Unlike mature targeted therapies for oncogene-driven NSCLC such as epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK), there is currently no approved standard targeted therapy for NSCLC with HER2 alterations (2). This evidence concerns the gene EGFR and non-small cell lung carcinoma.